CLBT Cellebrite DI Ltd.

Nasdaq cellebrite.com


$ 19.53 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 07:56:14 EDT
QQQ $ 605.43 $ 0.00 (0 %)
DIA $ 463.58 $ 0.00 (0 %)
SPY $ 667.59 $ 0.00 (0 %)
TLT $ 90.99 $ 0.00 (0 %)
GLD $ 390.39 $ 0.00 (0 %)
$ 19.3
$ 19.56
$ 19.33 x 1
$ 19.51 x 162
-- - --
$ 13.10 - $ 26.30
1,229,070
na
4.62B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-cellebrite-di-raises-price-target-to-23

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 t...

 lake-street-maintains-buy-on-cellebrite-di-lowers-price-target-to-22

Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to...

 needham-maintains-buy-on-cellebrite-di-lowers-price-target-to-18

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.

 cellebrite-di-sees-q3-sales-121000m-126000m-vs-124357m-est

Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.

 cellebrite-di-lowers-fy2025-sales-guidance-from-470000m-485000m-to-465000m-475000m-vs-474952m-est

Cellebrite DI (NASDAQ:CLBT) lowers FY2025 sales outlook from $470.000 million-$485.000 million to $465.000 million-$475.000 mil...

 cellebrite-di-q2-adj-eps-012-beats-010-estimate-sales-113276m-beat-112206m-estimate

Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 b...

 needham-reiterates-buy-on-cellebrite-di-maintains-24-price-target

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.

 cellebrite-agrees-to-acquire-corellium-for-enterprise-value-of-170m-in-cash-with-20m-converted-to-equity-at-closing

Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today ...

 needham-maintains-buy-on-cellebrite-di-lowers-price-target-to-24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $28 to $24.

 cellebrite-di-sees-q2-sales-110000m-116000m-vs-11534m-est

Cellebrite DI (NASDAQ:CLBT) sees Q2 sales of $110.000 million-$116.000 million vs $115.34 million analyst estimate.

 cellebrite-di-lowers-fy2025-sales-guidance-from-48000m-49000m-to-47000m-48500m-vs-48417m-est

Cellebrite DI (NASDAQ:CLBT) lowers FY2025 sales outlook from $480.00 million-$490.00 million to $470.00 million-$485.00 million...

 cellebrite-di-q1-adj-eps-010-beats-008-estimate-sales-10755m-miss-10936m-estimate

Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 b...

 jp-morgan-maintains-overweight-on-cellebrite-di-lowers-price-target-to-25

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $29 t...

 needham-reiterates-buy-on-cellebrite-di-maintains-28-price-target

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $28 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION